McIlrath & Eck’s Charles River Laboratories CRL Stock Holding History

McIlrath & Eck’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-25	Closed	-$4.62K	–	946
2024 Q4	$4.62K	Sell	25 -10	-29%	-$1.93K	﹤0.01%	773
2024 Q3	$6.89K	Buy	+35	New	+$7.27K	﹤0.01%	697
2024 Q2	–	Sell	-28	Closed	-$7.59K	–	959
2024 Q1	$7.59K	Hold	28	–	–	﹤0.01%	646
2023 Q4	$6.62K	Hold	28	–	–	﹤0.01%	627
2023 Q3	$5.49K	Hold	28	–	–	﹤0.01%	638
2023 Q2	$5.89K	Hold	28	–	–	﹤0.01%	642
2023 Q1	$5.65K	Hold	28	–	–	﹤0.01%	644
2022 Q4	$6.1K	Hold	28	–	–	﹤0.01%	604
2022 Q3	$6K	Hold	28	–	–	﹤0.01%	602
2022 Q2	$6K	Hold	28	–	–	﹤0.01%	580
2022 Q1	$8K	Hold	28	–	–	﹤0.01%	555
2021 Q4	$11K	Hold	28	–	–	﹤0.01%	520
2021 Q3	$12K	Hold	28	–	–	﹤0.01%	491
2021 Q2	$10K	Hold	28	–	–	﹤0.01%	516
2021 Q1	$8K	Hold	28	–	–	﹤0.01%	506
2020 Q4	$7K	Hold	28	–	–	﹤0.01%	474
2020 Q3	$6K	Hold	28	–	–	﹤0.01%	452
2020 Q2	$5K	Buy	+28	New	+$4.47K	﹤0.01%	463

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

McIlrath & Eck's CRL Position: Q1 2025 in Review

McIlrath & Eck sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 25 shares — an estimated $4.62K sold.

McIlrath & Eck first reported a position in CRL in Q2 2020 and held it in 18 quarters. The position peaked at $12K in Q3 2021. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

McIlrath & Eck reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
McIlrath & Eck sold 25 Charles River Laboratories shares in Q1 2025, an estimated $4.62K.
McIlrath & Eck first reported a position in Charles River Laboratories in Q2 2020 and held it in 18 quarters.
McIlrath & Eck's Charles River Laboratories position peaked at $12K in Q3 2021.
561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on McIlrath & Eck's 13F filing for Q1 2025, filed 16 May 2025.